Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE PAOLI-BRUNO

Allopathic & Osteopathic Physicians Family Medicine

NPI
1982601159
CMS profile
419826
Location
MEDLEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$120.40

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $120.40 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Allergan Inc. $120.40 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE PAOLI-BRUNO

NPI 1982601159 · CMS profile ID 419826

Allopathic & Osteopathic Physicians / Family Medicine

MEDLEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE PAOLI-BRUNO, NPI 1982601159, CMS profile ID 419826. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JORGE PAOLI-BRUNO, NPI 1982601159, CMS profile ID 419826. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JORGE PAOLI-BRUNO, NPI 1982601159, CMS profile ID 419826, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $120.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan Inc. $120.4010/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670916157 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $120.40 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $961,612.31 249
PY2024 Recipient $4,214.80 1
PY2024 Principal investigator $2,148,310.31 277
PY2023 Principal investigator $1,000,560.67 172
PY2022 Recipient $253.00 2
PY2022 Principal investigator $730,831.67 34
PY2021 Recipient $1,654.33 2
PY2021 Principal investigator $437,077.46 64
PY2020 Recipient $2,885.98 3
PY2020 Principal investigator $359,635.45 60
PY2019 Principal investigator $605,972.33 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

278 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Braintree Laboratories, Inc. $302.05 12/31/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204900
Principal investigator 1 GlaxoSmithKline, LLC. $33,373.90 12/19/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 1156000577
Principal investigator 1 Chiesi USA, Inc. $6,627.00 12/04/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148225520
Principal investigator 1 Braintree Laboratories, Inc. $73,500.00 11/14/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204192
Principal investigator 1 Chiesi USA, Inc. $4,259.00 11/06/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148224728
Principal investigator 1 IBSA Institut Biochimique SA $15,445.30 10/30/2024 Non-covered Recipient Entity
PCRS NETWORK LLC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1142342385
Principal investigator 1 IBSA Institut Biochimique SA $18,097.30 10/30/2024 Non-covered Recipient Entity
PCRS NETWORK LLC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1142342387
Principal investigator 1 IBSA Institut Biochimique SA $22,917.70 10/30/2024 Non-covered Recipient Entity
PCRS NETWORK LLC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1142342389
Principal investigator 1 IBSA Institut Biochimique SA $23,956.40 10/30/2024 Non-covered Recipient Entity
PCRS NETWORK LLC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1142342391
Principal investigator 1 IBSA Institut Biochimique SA $10,952.50 10/30/2024 Non-covered Recipient Entity
PCRS NETWORK LLC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1142342655
Principal investigator 1 IBSA Institut Biochimique SA $83,912.40 10/18/2024 Non-covered Recipient Entity
PCRS NETWORK LLC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1142342331
Principal investigator 1 Chiesi USA, Inc. $3,314.00 10/09/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148223930
Principal investigator 1 Braintree Laboratories, Inc. $42,000.00 10/08/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203050
Principal investigator 1 Braintree Laboratories, Inc. $9,336.74 10/03/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202808
Principal investigator 1 Braintree Laboratories, Inc. $6,525.90 10/03/2024 Non-covered Recipient Entity
KERLO RESEARCH INC
A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroesophageal Reflux Disease No dispute reported 06/30/2026 1120202960
Recipient Eli Lilly and Company $4,214.80 09/24/2024 Covered Recipient Physician A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1137348077
Principal investigator 1 Chiesi USA, Inc. $13,298.00 09/18/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148223156
Principal investigator 1 Chiesi USA, Inc. $5,682.00 08/09/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148222278
Principal investigator 1 Chiesi USA, Inc. $415.13 07/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221672
Principal investigator 1 Chiesi USA, Inc. $6,120.51 07/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221674
Principal investigator 1 Chiesi USA, Inc. $415.13 07/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221676
Principal investigator 1 Chiesi USA, Inc. $415.13 07/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221936
Principal investigator 1 Chiesi USA, Inc. $6,120.51 07/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221938
Principal investigator 1 Chiesi USA, Inc. $415.13 07/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221940
Principal investigator 1 Chiesi USA, Inc. $415.13 07/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221942
Principal investigator 1 Chiesi USA, Inc. $6,120.51 07/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221944
Principal investigator 1 Chiesi USA, Inc. $415.13 07/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221946
Principal investigator 1 Chiesi USA, Inc. $1,776.59 07/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221948
Principal investigator 1 Chiesi USA, Inc. $6,120.51 07/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221950
Principal investigator 1 Braintree Laboratories, Inc. $17,122.50 07/25/2024 Non-covered Recipient Entity
KERLO RESEARCH INC
A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroesophageal Reflux Disease No dispute reported 06/30/2026 1120201232
Principal investigator 1 Braintree Laboratories, Inc. $28,671.22 07/23/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120201170
Principal investigator 1 Braintree Laboratories, Inc. $28,843.16 07/19/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200892
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154160373
Principal investigator 1 CIPLA USA INC. $132.00 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154160459
Principal investigator 1 CIPLA USA INC. $423.72 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154160461
Principal investigator 1 CIPLA USA INC. $29.32 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154160463
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154160465
Principal investigator 1 CIPLA USA INC. $132.00 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154160467
Principal investigator 1 CIPLA USA INC. $168.58 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154160469
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161045
Principal investigator 1 CIPLA USA INC. $29.32 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161047
Principal investigator 1 CIPLA USA INC. $215.67 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161049
Principal investigator 1 CIPLA USA INC. $168.58 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161051
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161053
Principal investigator 1 CIPLA USA INC. $215.67 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161055
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161129
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161131
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161133
Principal investigator 1 CIPLA USA INC. $132.00 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161135
Principal investigator 1 CIPLA USA INC. $215.67 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161137
Principal investigator 1 CIPLA USA INC. $132.00 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161139
Principal investigator 1 CIPLA USA INC. $168.58 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161179
Principal investigator 1 CIPLA USA INC. $29.32 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161181
Principal investigator 1 CIPLA USA INC. $132.00 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161183
Principal investigator 1 CIPLA USA INC. $29.32 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161185
Principal investigator 1 CIPLA USA INC. $168.58 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161187
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161225
Principal investigator 1 CIPLA USA INC. $132.00 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161227
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161229
Principal investigator 1 CIPLA USA INC. $29.32 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161231
Principal investigator 1 CIPLA USA INC. $423.72 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161233
Principal investigator 1 CIPLA USA INC. $29.32 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161235
Principal investigator 1 CIPLA USA INC. $168.58 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161273
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161275
Principal investigator 1 CIPLA USA INC. $29.32 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161277
Principal investigator 1 CIPLA USA INC. $215.67 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161279
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161281
Principal investigator 1 CIPLA USA INC. $168.58 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161283
Principal investigator 1 CIPLA USA INC. $423.72 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161429
Principal investigator 1 CIPLA USA INC. $168.58 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161431
Principal investigator 1 CIPLA USA INC. $423.72 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161433
Principal investigator 1 CIPLA USA INC. $168.58 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161435
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161437
Principal investigator 1 CIPLA USA INC. $423.72 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161439
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161513
Principal investigator 1 CIPLA USA INC. $423.72 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161515
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161517
Principal investigator 1 CIPLA USA INC. $423.72 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161519
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161521
Principal investigator 1 CIPLA USA INC. $29.32 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161523
Principal investigator 1 CIPLA USA INC. $29.32 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161561
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161563
Principal investigator 1 CIPLA USA INC. $132.00 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161565
Principal investigator 1 CIPLA USA INC. $423.72 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161567
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161569
Principal investigator 1 CIPLA USA INC. $132.00 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161571
Principal investigator 1 CIPLA USA INC. $423.72 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161897
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161899
Principal investigator 1 CIPLA USA INC. $215.67 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161901
Principal investigator 1 CIPLA USA INC. $423.72 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161903
Principal investigator 1 CIPLA USA INC. $423.72 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161905
Principal investigator 1 CIPLA USA INC. $215.67 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161907
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161969
Principal investigator 1 CIPLA USA INC. $132.00 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161971
Principal investigator 1 CIPLA USA INC. $215.67 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161973
Principal investigator 1 CIPLA USA INC. $168.58 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161975
Principal investigator 1 CIPLA USA INC. $215.67 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161977
Principal investigator 1 CIPLA USA INC. $132.00 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154161979
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154162029
Principal investigator 1 CIPLA USA INC. $29.32 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154162031
Principal investigator 1 CIPLA USA INC. $423.72 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154162033
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154162035
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154162037
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154162039
Principal investigator 1 CIPLA USA INC. $215.67 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154162077
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154162079
Principal investigator 1 CIPLA USA INC. $132.00 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154162081
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154162083
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154162085
Principal investigator 1 CIPLA USA INC. $215.67 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154162087
Principal investigator 1 CIPLA USA INC. $215.67 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163243
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163245
Principal investigator 1 CIPLA USA INC. $29.32 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163247
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163249
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163251
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163253
Principal investigator 1 CIPLA USA INC. $423.72 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163375
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163377
Principal investigator 1 CIPLA USA INC. $215.67 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163379
Principal investigator 1 CIPLA USA INC. $215.67 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163381
Principal investigator 1 CIPLA USA INC. $132.00 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163383
Principal investigator 1 CIPLA USA INC. $423.72 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163385
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163435
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163437
Principal investigator 1 CIPLA USA INC. $168.58 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163439
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163441
Principal investigator 1 CIPLA USA INC. $132.00 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163443
Principal investigator 1 CIPLA USA INC. $29.32 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163445
Principal investigator 1 CIPLA USA INC. $29.32 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163483
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163485
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163487
Principal investigator 1 CIPLA USA INC. $215.67 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163489
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163491
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163493
Principal investigator 1 CIPLA USA INC. $215.67 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163519
Principal investigator 1 CIPLA USA INC. $168.58 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163521
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163523
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163525
Principal investigator 1 CIPLA USA INC. $168.58 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163527
Principal investigator 1 CIPLA USA INC. $423.72 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163529
Principal investigator 1 CIPLA USA INC. $43.02 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163543
Principal investigator 1 CIPLA USA INC. $168.58 07/12/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1154163545
Principal investigator 1 Chiesi USA, Inc. $6,671.00 07/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148221260
Principal investigator 1 GlaxoSmithKline, LLC. $692.10 07/08/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127536028
Principal investigator 1 Eli Lilly and Company $1,415.50 06/25/2024 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 1137359475
Principal investigator 1 GlaxoSmithKline, LLC. $10,872.00 06/19/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127536038
Principal investigator 1 Chiesi USA, Inc. $9,992.00 06/14/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148220636
Principal investigator 1 Chiesi USA, Inc. $1,214.73 06/14/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148220666
Principal investigator 1 Chiesi USA, Inc. $2,492.08 06/14/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148220672
Principal investigator 1 GlaxoSmithKline, LLC. $2,003.40 06/14/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127536036
Principal investigator 1 Braintree Laboratories, Inc. $8,845.86 06/13/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120200480
Principal investigator 1 Braintree Laboratories, Inc. $8,845.86 06/13/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120200520
Principal investigator 1 IBSA Institut Biochimique SA $24,260.60 06/12/2024 Non-covered Recipient Entity
PCRS NETWORK LLC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1142342127
Principal investigator 1 Chiesi USA, Inc. $10,461.00 05/15/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148219886
Principal investigator 1 GlaxoSmithKline, LLC. $1,917.00 05/08/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127536034
Principal investigator 1 Chiesi USA, Inc. $6,120.51 04/26/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218990
Principal investigator 1 Chiesi USA, Inc. $6,120.51 04/26/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218992
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/26/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218994
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/26/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218996
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/26/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218998
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/26/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148219000
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/26/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148219220
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/26/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148219222
Principal investigator 1 Chiesi USA, Inc. $5,962.40 04/26/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148219224
Principal investigator 1 Chiesi USA, Inc. $2,492.08 04/26/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148219226
Principal investigator 1 Chiesi USA, Inc. $1,214.73 04/26/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148219228
Principal investigator 1 Braintree Laboratories, Inc. $52,500.00 04/19/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199886
Principal investigator 1 Braintree Laboratories, Inc. $52,500.00 04/19/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199934
Principal investigator 1 Braintree Laboratories, Inc. $8,188.20 04/15/2024 Non-covered Recipient Entity
KERLO RESEARCH INC
A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroesophageal Reflux Disease No dispute reported 06/30/2026 1120199804
Principal investigator 1 Eli Lilly and Company $474.64 04/15/2024 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1137359233
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218169
Principal investigator 1 Chiesi USA, Inc. $415.13 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218171
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218173
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218175
Principal investigator 1 Chiesi USA, Inc. $415.13 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218177
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218179
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218181
Principal investigator 1 Chiesi USA, Inc. $1,214.73 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218183
Principal investigator 1 Chiesi USA, Inc. $1,214.73 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218185
Principal investigator 1 Chiesi USA, Inc. $415.13 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218187
Principal investigator 1 Chiesi USA, Inc. $2,492.08 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218189
Principal investigator 1 Chiesi USA, Inc. $1,214.73 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218191
Principal investigator 1 Chiesi USA, Inc. $1,214.73 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218193
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218195
Principal investigator 1 Chiesi USA, Inc. $6,120.51 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218197
Principal investigator 1 Chiesi USA, Inc. $6,120.51 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218199
Principal investigator 1 Chiesi USA, Inc. $6,120.51 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218201
Principal investigator 1 Chiesi USA, Inc. $2,492.08 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218203
Principal investigator 1 Chiesi USA, Inc. $5,962.40 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218205
Principal investigator 1 Chiesi USA, Inc. $5,962.40 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218207
Principal investigator 1 Chiesi USA, Inc. $1,214.73 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218209
Principal investigator 1 Chiesi USA, Inc. $2,492.08 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218211
Principal investigator 1 Chiesi USA, Inc. $2,492.08 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218685
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218687
Principal investigator 1 Chiesi USA, Inc. $2,492.08 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218689
Principal investigator 1 Chiesi USA, Inc. $5,962.40 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218691
Principal investigator 1 Chiesi USA, Inc. $5,962.40 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218693
Principal investigator 1 Chiesi USA, Inc. $415.13 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218695
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218697
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218699
Principal investigator 1 Chiesi USA, Inc. $5,962.40 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218701
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218703
Principal investigator 1 Chiesi USA, Inc. $13,817.52 04/05/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148217745
Principal investigator 1 Braintree Laboratories, Inc. $70,000.00 04/04/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199598
Principal investigator 1 Braintree Laboratories, Inc. $70,000.00 04/04/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199600
Principal investigator 1 Braintree Laboratories, Inc. $70,000.00 04/04/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199676
Principal investigator 1 Braintree Laboratories, Inc. $70,000.00 04/04/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199678
Principal investigator 1 Braintree Laboratories, Inc. $35,000.00 03/27/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199506
Principal investigator 1 Braintree Laboratories, Inc. $35,000.00 03/27/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199532
Principal investigator 1 Braintree Laboratories, Inc. $70,000.00 03/21/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199468
Principal investigator 1 Braintree Laboratories, Inc. $70,000.00 03/21/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199470
Principal investigator 1 Braintree Laboratories, Inc. $66,500.00 03/21/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199472
Principal investigator 1 Braintree Laboratories, Inc. $70,000.00 03/21/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199488
Principal investigator 1 Braintree Laboratories, Inc. $70,000.00 03/21/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199490
Principal investigator 1 Braintree Laboratories, Inc. $66,500.00 03/21/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199492
Principal investigator 1 GlaxoSmithKline, LLC. $1,341.90 03/13/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127536030
Principal investigator 1 Braintree Laboratories, Inc. $46,660.88 03/11/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199130
Principal investigator 1 Braintree Laboratories, Inc. $46,660.88 03/11/2024 Non-covered Recipient Entity
KERLO RESEARCH
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199164
Principal investigator 1 Chiesi USA, Inc. $908.00 03/08/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148216961
Principal investigator 1 Chiesi USA, Inc. $2,521.00 02/21/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148216296
Principal investigator 1 GlaxoSmithKline, LLC. $836.10 02/02/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127536032
Principal investigator 1 Eli Lilly and Company $7,850.00 01/30/2024 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1137356957
Principal investigator 1 Chiesi USA, Inc. $5,962.40 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214926
Principal investigator 1 Chiesi USA, Inc. $1,776.59 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214928
Principal investigator 1 Chiesi USA, Inc. $1,776.59 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214930
Principal investigator 1 Chiesi USA, Inc. $5,962.40 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214932
Principal investigator 1 Chiesi USA, Inc. $1,214.73 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214934
Principal investigator 1 Chiesi USA, Inc. $1,776.59 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214936
Principal investigator 1 Chiesi USA, Inc. $1,214.73 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214938
Principal investigator 1 Chiesi USA, Inc. $1,776.59 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214940
Principal investigator 1 Chiesi USA, Inc. $1,776.59 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214942
Principal investigator 1 Chiesi USA, Inc. $415.13 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214944
Principal investigator 1 Chiesi USA, Inc. $1,776.59 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214946
Principal investigator 1 Chiesi USA, Inc. $1,214.73 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214948
Principal investigator 1 Chiesi USA, Inc. $6,120.51 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214950
Principal investigator 1 Chiesi USA, Inc. $1,214.73 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214952
Principal investigator 1 Chiesi USA, Inc. $5,962.40 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214954
Principal investigator 1 Chiesi USA, Inc. $5,962.40 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214956
Principal investigator 1 Chiesi USA, Inc. $1,214.73 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214958
Principal investigator 1 Chiesi USA, Inc. $1,214.73 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214960
Principal investigator 1 Chiesi USA, Inc. $1,214.73 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214962
Principal investigator 1 Chiesi USA, Inc. $415.13 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214964
Principal investigator 1 Chiesi USA, Inc. $1,776.59 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214966
Principal investigator 1 Chiesi USA, Inc. $2,492.08 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214968
Principal investigator 1 Chiesi USA, Inc. $1,214.73 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214970
Principal investigator 1 Chiesi USA, Inc. $2,492.08 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214972
Principal investigator 1 Chiesi USA, Inc. $1,776.59 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214974
Principal investigator 1 Chiesi USA, Inc. $1,776.59 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148214976
Principal investigator 1 Chiesi USA, Inc. $415.13 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215698
Principal investigator 1 Chiesi USA, Inc. $2,492.08 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215700
Principal investigator 1 Chiesi USA, Inc. $1,776.59 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215708
Principal investigator 1 Chiesi USA, Inc. $1,776.59 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215712
Principal investigator 1 Chiesi USA, Inc. $415.13 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215716
Principal investigator 1 Chiesi USA, Inc. $1,776.59 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215724
Principal investigator 1 Chiesi USA, Inc. $415.13 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215726
Principal investigator 1 Chiesi USA, Inc. $2,492.08 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215728
Principal investigator 1 Chiesi USA, Inc. $1,776.59 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215730
Principal investigator 1 Chiesi USA, Inc. $6,120.51 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215732
Principal investigator 1 Chiesi USA, Inc. $1,776.59 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215734
Principal investigator 1 Chiesi USA, Inc. $2,492.08 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215736
Principal investigator 1 Chiesi USA, Inc. $5,962.40 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215738
Principal investigator 1 Chiesi USA, Inc. $6,120.51 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215740
Principal investigator 1 Chiesi USA, Inc. $2,492.08 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215742
Principal investigator 1 Chiesi USA, Inc. $5,962.40 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215744
Principal investigator 1 Chiesi USA, Inc. $2,492.08 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215746
Principal investigator 1 Chiesi USA, Inc. $1,776.59 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215748
Principal investigator 1 Chiesi USA, Inc. $2,492.08 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215750
Principal investigator 1 Chiesi USA, Inc. $5,962.40 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215752
Principal investigator 1 Chiesi USA, Inc. $6,120.51 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215754
Principal investigator 1 Chiesi USA, Inc. $6,120.51 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215756
Principal investigator 1 Chiesi USA, Inc. $5,962.40 01/29/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215758
Principal investigator 1 Eli Lilly and Company $23,795.97 01/25/2024 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 1137358527
Principal investigator 1 Braintree Laboratories, Inc. $18,657.90 01/15/2024 Non-covered Recipient Entity
KERLO RESEARCH INC
A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroesophageal Reflux Disease No dispute reported 06/30/2026 1120198380
Principal investigator 1 Chiesi USA, Inc. $3,397.00 01/10/2024 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148214335
Principal investigator 1 Eli Lilly and Company $20,606.00 01/09/2024 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 1137358525
Principal investigator 1 Eli Lilly and Company $1,232.84 01/08/2024 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1137359405
Principal investigator 1 Eli Lilly and Company $20,958.00 01/02/2024 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1137356955
Principal investigator 1 Eli Lilly and Company $224,806.00 01/02/2024 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 1137359231